BioLineRx (BLRX) Total Debt (QoQ) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.30% |
| Sep 30, 2025 | -9.99% |
| Jun 30, 2025 | -9.09% |
| Mar 31, 2025 | -8.34% |
| Dec 31, 2024 | -51.67% |
| Sep 30, 2024 | -5.58% |
| Jun 30, 2024 | 206.16% |
| Mar 31, 2024 | -1.59% |
| Dec 31, 2023 | -15.28% |
| Sep 30, 2023 | -0.32% |
| Jun 30, 2023 | 7.18% |
| Mar 31, 2023 | 6.20% |
| Dec 31, 2022 | 11.06% |
| Sep 30, 2022 | 803.75% |
| Jun 30, 2022 | -46.77% |
| Mar 31, 2022 | -30.98% |
| Dec 31, 2021 | -22.88% |
| Sep 30, 2021 | -18.00% |
| Jun 30, 2021 | -14.69% |
| Mar 31, 2021 | -12.36% |
| Dec 31, 2020 | -10.59% |
| Sep 30, 2020 | -9.35% |
| Jun 30, 2020 | -8.37% |
| Mar 31, 2020 | -7.51% |
| Dec 31, 2019 | -7.46% |
| Sep 30, 2019 | 2.19% |
| Jun 30, 2019 | 1.29% |
| Mar 31, 2019 | 1.50% |
| Dec 31, 2018 | 10,054.65% |
| Sep 30, 2018 | -21.10% |
| Jun 30, 2018 | -18.05% |
| Mar 31, 2018 | -46.80% |
| Dec 31, 2017 | 38.89% |
| Sep 30, 2017 | -11.33% |
| Jun 30, 2017 | -10.57% |
| Mar 31, 2017 | -33.82% |
| Dec 31, 2016 | 26.10% |
| Sep 30, 2016 | -8.11% |
| Jun 30, 2016 | -7.50% |
| Mar 31, 2016 | -6.98% |
| Dec 31, 2015 | -6.01% |